Australis Capital (DB:AC4) - Aandelenkoers, Nieuws & Analyse

AC4 Overzicht aandelen

Operates as a cannabis company. Meer informatie

AC4 fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	3/6
Dividenden	0/6

Risicoanalyse

De winst is de afgelopen 5 jaar met 53.2% per jaar gedaald

Heeft geen betekenisvolle marktkapitalisatie ( €9M )

Aandelen zijn zeer illiquide

Aandeelhouders zijn het afgelopen jaar verwaterd

Australis Capital Inc. Concurrenten

MPH Health Care

DB:93M1

€105.3m

Biofrontera

XTRA:B8FK

€15.8m

SynBiotic

DUSE:SBX

€27.9m

Redx Pharma

DB:0RX

€65.0m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Australis Capital
Historische aandelenkoersen
Huidige aandelenkoers	CA$0.0085
52 Week Hoogtepunt	CA$0.092
52 Week Laag	CA$0.005
Bèta	1.13
11 maand verandering	0%
3 maanden verandering	70.00%
1 Jaar Verandering	-90.34%
33 jaar verandering	-97.09%
5 jaar verandering	n/a
Verandering sinds IPO	-98.46%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	AC4	DE Pharmaceuticals	DE Markt
7D	0%	1.4%	0.8%
1Y	-90.3%	-18.4%	9.1%

Rendement versus industrie: AC4 presteerde slechter dan de German Pharmaceuticals -sector, die het afgelopen jaar een rendement van -18.4 % opleverde.

Rendement versus markt: AC4 presteerde slechter dan German Market, dat het afgelopen jaar een rendement van 9.1 % opleverde.

Prijsvolatiliteit

Is AC4's price volatile compared to industry and market?
AC4 volatility
AC4 Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	6.9%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.8%
10% least volatile stocks in DE Market	2.4%

Stabiele aandelenkoers: De aandelenkoers van AC4 is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: Onvoldoende gegevens om de volatiliteitsverandering van AC4 in het afgelopen jaar te bepalen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2015	n/a	Terry Booth	www.ausacap.com

Australis Capital Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Australis Capital zich tot de beurswaarde?
AC4 fundamentele statistieken
Marktkapitalisatie	€6.03m
Inkomsten(TTM)	-€34.52m
Inkomsten(TTM)	€6.53m

0.9x

P/S-verhouding

-0.2x

Koers/Winstverhouding

Is AC4 overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
AC4 resultatenrekening (TTM)
Inkomsten	CA$9.47m
Kosten van inkomsten	CA$3.61m
Brutowinst	CA$5.87m
Overige uitgaven	CA$55.96m
Inkomsten	-CA$50.09m

Laatst gerapporteerde inkomsten

Mar 31, 2022

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.14
Brutomarge	61.95%
Nettowinstmarge	-528.67%
Schuld/Eigen Vermogen Verhouding	5.4%

Hoe presteerde AC4 op de lange termijn?

Bekijk historische prestaties en vergelijking

AC4 Overzicht aandelen

Risicoanalyse

Australis Capital Inc. Concurrenten

DB:93M1

€105.3m

XTRA:B8FK

€15.8m

DUSE:SBX

€27.9m

DB:0RX

€65.0m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Australis Capital Inc. Announces Executive Changes

Australis Capital Inc Completes Final New Jersey License Application Step

Australis Capital Inc. Announces Board Changes

Full year 2022 earnings released: CA$0.20 loss per share (vs CA$0.14 loss in FY 2021)

Australis Capital Inc. Appoints Jill Swainson as Member of Board of Directors

High number of new and inexperienced directors

Recent updates

Australis Capital Inc. Announces Executive Changes

Australis Capital Inc Completes Final New Jersey License Application Step

Australis Capital Inc. Announces Board Changes

Full year 2022 earnings released: CA$0.20 loss per share (vs CA$0.14 loss in FY 2021)

Australis Capital Inc. Appoints Jill Swainson as Member of Board of Directors

High number of new and inexperienced directors

Australis Capital Inc. Announces Mr. Natural, an AUDACIOUS Brand, Launched Its First Product in Nevada: Full Spectrum Hash RSO

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Australis Capital Inc. to Report Q3, 2022 Results on Mar 01, 2022

Australis Capital Inc. (CNSX:AUSA) completed the acquisition of Gary Maverick Inc. for $0.5 million.

Australis Capital Inc. announced that it expects to receive CAD 20 million in funding

Second quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Australis Capital Inc. announced that it expects to receive CAD 15 million in funding

Toro Pacific Management Inc. acquired 5.8% stake in Body and Mind Inc. (OTCPK:BMMJ) from Australis Capital Inc. (CNSX:AUSA) for CAD 1.8 million.

No independent directors

Australis Capital Inc. (CNSX:AUSA) agreed to acquire Gary Maverick Inc.

Australis Capital Inc. Intends to Launch Additional Products Lines Under the New Name

Australis Capital Inc. (CNSX:AUSA) completed the acquisition of 51% in 2750176 Ontario Inc. from shareholders.

Australis Capital Inc. Announces Management Changes

Australis Capital Inc. and 3 Rivers Biotech Inc. Enter into Tissue Culture Joint Venture

Third quarter 2021 earnings released: CA$0.11 loss per share (vs CA$0.041 loss in 3Q 2020)

Australis Capital Inc. and Cann Group Limited Sign Agreement

New 90-day high: €0.30

Australis Capital Inc. (CNSX:AUSA) entered into a non-binding term sheet to acquire 51% in 2750176 Ontario Inc. from shareholders for CAD 25.9 million.

Australis Capital Inc. (CNSX:AUSA) signed a non-binding term sheet to acquire Green Therapeutics LLC for CAD 10 million.

Australis Capital Inc. Appoints Jon Paul as its New CFO

Second quarter 2021 earnings released: CA$0.034 loss per share

Australis Capital Inc. Announces Management Changes

Australis Capital Inc. Announces Chief Executive Officer Changes

Australis Capital Inc. Appoints Sameer Kumar as Independent Member of its Board of Directors

First quarter earnings released

Australis Capital Inc. (CNSX:AUSA) completed the acquisition of Paytron, LLC.